MBOT, US59503A2042

Microbot Medical stock fell 3.33 percent on October 2 as analysts held a Hold consensus

Published on 10/04/2026 at 20:46 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Microbot Medical stock closed at USD 1.16 on Nasdaq, while five analysts set a Hold consensus and a USD 6.375 average target. Q2 revenue reached USD 0.24 million.

MBOT, US59503A2042, Illustration mit AI erstellt.

Microbot Medical (ISIN US59503A2042) stock fell 3.33 percent to USD 1.16 on Nasdaq on October 2, 2026, with 852,404 shares traded. The latest company update dated September 25, 2026, outlined wider U.S. commercialization for the LIBERTY endovascular robotic system and a target of 12 sales territories by year-end, according to GlobeNewswire.

Revenue beats the consensus estimate

Microbot Medical reported USD 0.24 million in revenue for Q2 2026, compared with a USD 0.13 million consensus estimate. The company also reported adjusted EPS of negative USD 0.08, matching the estimate, according to MarketBeat on September 23, 2026. The revenue comparison is important because the company remains in a commercialization phase rather than a mature recurring-revenue model.

Analysts see a wide valuation gap

MarketBeat reported on September 23, 2026, that five analysts gave Microbot Medical a consensus rating of Hold, comprising three Buy ratings, one Hold rating and one Sell rating. The average 12-month price target was USD 6.375, which lies 449.57 percent above the October 2 price of USD 1.16.

That spread places execution at the center of the investment case. Microbot said on September 25, 2026, that it had added three Area Sales Managers and one Regional Sales Director, while it expects positive gross margins in 2027 and CE mark approval in late Q4 2026 or early Q1 2027, according to GlobeNewswire.

Stock remains near its yearly low

Microbot Medical closed at USD 1.16 on Nasdaq on October 2, 2026, within its USD 1.14 to USD 3.46 52-week range. Its market capitalization was USD 52.9 million on the same date, leaving the share price 66.47 percent below the 52-week high.